Search
Metronidazole
go.drugbank.com/drugs/DB00916ApprovedInvestigationalMetronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic inf...
MUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalDendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.
Levothyroxine
go.drugbank.com/drugs/DB00451ApprovedInvestigational[F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland.
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10990ApprovedHaemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemoph...
Cholestyramine
go.drugbank.com/drugs/DB01432ApprovedInvestigationalCholestyramine resin is quite hydrophilic, but insoluble in water.